Neuronetics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel L. Reuvers
- Full Time Employees
- 658
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3222 Phoenixville Pike Malvern PA United States of America 19355
- IPO Date
- Jun 28, 2018
- CIK
- 0001227636
- Website
- neurostar.com
- Similar Companies
- Business
- Neuronetics, Inc. (NASDAQ: STIM) develops and commercializes non-invasive transcranial magnetic stimulation (TMS) therapies for psychiatric and neurological disorders, primarily targeting patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression; its core offering is the NeuroStar Advanced Therapy System, an FDA-cleared office-based device that delivers MRI-strength magnetic pulses to stimulate brain regions associated with mood regulation, supplemented by the TrakStar cloud-based platform for patient data management, treatment tracking, and outcome analytics; additional services encompass clinical training, reimbursement support, and provider practice optimization tools. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company operates primarily in the United States through a network of provider practices and internationally in select markets, serving psychiatrists, mental health professionals, and treatment-resistant patients across adolescent (ages 15-21), adult, and Medicare populations. In December 2024, Neuronetics completed the acquisition of Greenbrook TMS Inc., integrating over 95 U.S. treatment clinics to expand its service delivery model and realize over $22 million in annualized cost synergies while targeting double-digit revenue growth and cash flow positivity in 2025; recent FDA clearances extend NeuroStar use as an adjunct to antidepressants in adolescents with MDD, alongside expanded insurer coverage including TRICARE in 23 states, Cigna, Aetna, Humana, and Medicare; the company also launched the Better Me Provider network to boost patient treatment volumes and announced strategic partnerships such as a five-year exclusive alliance with Transformations Care Network.
Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
Neuronetics Appoints Robert Greene as Senior Vice President Sales
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Neuronetics Announces Chief Financial Officer Transition
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Jorey Chernett Acquires 450,000 Shares of Neuronetics (NASDAQ:STIM) Stock
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Analyzing ADB International Group (OTCMKTS:EQUR) & Neuronetics (NASDAQ:STIM)
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?